



OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH Circular 47/2020
DH 581/2020

20th May 2020

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Fulvestrant 250mg solution for injection

It is being brought to your attention that Fulvestrant 250mg solution for injection is now available on the Government Formulary List for in-patient use.

Fulvestrant is a competitive oestrogen receptor (ER) antagonist with an affinity comparable to oestradiol.

Fulvestrant 250mg solution for injection can be prescribed by Consultant Oncologist as per protocol 79 attached (Annex 1).

For your attention please.

Dr Denis Vella Baldacchino
Chief Medical Officer

Fulvestrant 250mg Solution for Injection

Prescriber Criteria: Consultant Oncologist

In-patient use:

For the treatment of HR positive, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

Duration of Approval:

1 year